Clinical trial
Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation
NCT00281554 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00281554 |
|---|---|
| Title | Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation |
| Official title | A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation |
| Acronym | ACT 4 |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Advanz Pharma Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | RSD1235 |
| Enrollment | 254 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Jan 25, 2006 |
| Last update posted | Apr 3, 2008 |
| Countries | Argentina, Canada, Denmark, South Africa, Sweden, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: